These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. Shining a light on cell signaling in leukemia through proteomics: relevance for the clinic. Hoff FW; Hu CW; Qutub AA; de Bont ESJM; Horton TM; Kornblau SM Expert Rev Proteomics; 2018 Jul; 15(7):613-622. PubMed ID: 29898608 [TBL] [Abstract][Full Text] [Related]
85. Reverse phase protein arrays in acute leukemia: investigative and methodological challenges. Hoff FW; Horton TM; Kornblau SM Expert Rev Proteomics; 2021 Dec; 18(12):1087-1097. PubMed ID: 34965151 [TBL] [Abstract][Full Text] [Related]
86. Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia. Reikvam H; Hemsing AL; Hernandez-Valladares M; Birkeland E Expert Rev Proteomics; 2022 Feb; 19(2):73-76. PubMed ID: 35436165 [No Abstract] [Full Text] [Related]
87. Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. Dowling P; Tierney C; Dunphy K; Miettinen JJ; Heckman CA; Bazou D; O'Gorman P Proteomes; 2021 Oct; 9(4):. PubMed ID: 34842843 [TBL] [Abstract][Full Text] [Related]
88. IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies. Meggendorfer M; Cappelli LV; Walter W; Haferlach C; Kern W; Falini B; Haferlach T Leukemia; 2018 May; 32(5):1249-1253. PubMed ID: 29568090 [No Abstract] [Full Text] [Related]
89. Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine. Hatfield KJ; Grønningsaeter IS; Reikvam H Curr Med Res Opin; 2021 Dec; 37(12):2107-2111. PubMed ID: 34498983 [TBL] [Abstract][Full Text] [Related]
91. Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades. Kantarjian HM; Short NJ; Fathi AT; Marcucci G; Ravandi F; Tallman M; Wang ES; Wei AH Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):580-597. PubMed ID: 34176779 [TBL] [Abstract][Full Text] [Related]
92. Proteomics-based prediction of clinical response in acute myeloid leukemia. Albitar M; Potts SJ; Giles FJ; O'Brien S; Jilani I; Donahue AC; Estey EH; Kantarjian H Exp Hematol; 2009 Jul; 37(7):784-90. PubMed ID: 19422784 [TBL] [Abstract][Full Text] [Related]
93. HLX in AML: novel prognostic and therapeutic target. Pandolfi A; Steidl U Oncotarget; 2012 Oct; 3(10):1059-60. PubMed ID: 23888188 [No Abstract] [Full Text] [Related]
94. Global Proteomic Profiling of Pediatric AML: A Pilot Study. Nguyen NHK; Wu H; Tan H; Peng J; Rubnitz JE; Cao X; Pounds S; Lamba JK Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202615 [TBL] [Abstract][Full Text] [Related]
95. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. Zeng AGX; Bansal S; Jin L; Mitchell A; Chen WC; Abbas HA; Chan-Seng-Yue M; Voisin V; van Galen P; Tierens A; Cheok M; Preudhomme C; Dombret H; Daver N; Futreal PA; Minden MD; Kennedy JA; Wang JCY; Dick JE Nat Med; 2022 Jun; 28(6):1212-1223. PubMed ID: 35618837 [TBL] [Abstract][Full Text] [Related]
96. Comparative proteomics in acute myeloid leukemia. Luczak M; Kaźmierczak M; Hadschuh L; Lewandowski K; Komarnicki M; Figlerowicz M Contemp Oncol (Pozn); 2012; 16(2):95-103. PubMed ID: 23788862 [TBL] [Abstract][Full Text] [Related]
99. New considerations in the design of clinical trials for the treatment of acute leukemia. Hourigan CS; Karp JE Clin Investig (Lond); 2011 Apr; 1(4):509-517. PubMed ID: 23459118 [TBL] [Abstract][Full Text] [Related]
100. Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape. Short NJ; Tallman MS; Pollyea DA; Ravandi F; Kantarjian H J Clin Oncol; 2021 Aug; 39(23):2535-2538. PubMed ID: 34043455 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]